RobertZOrlowskiMDPhD

PubMed

• 19 citations
  Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115
  Vaishali Sanchorawala, Antje Hoering, David C. Seldin, Kathleen T. Finn, Salli Fennessey
  Bone Marrow Transplantation. 2013-11-01
• 600 citations
  Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
  Antonio Palumbo, S V Rajkumar, Meletios A. Dimopoulos, Paul G. Richardson, J F San Miguel
  Leukemia. 2008-02-01
• 195 citations
  Management of treatment-emergent peripheral neuropathy in multiple myeloma
  Paul G. Richardson, Michel Delforge, Meral Beksac, Patrick Y. Wen, Joost L M Jongen
  Leukemia. 2012-04-01

Journal Articles

• Primary Plasma Cell Leukemia: Autologous Stem Cell Transplant in an Era of Novel Induction Drugs  
  Krina Patel, Rohtesh Mehta, Donna M Weber, Sheeba K Thomas, Nina Shah, Hans C Lee, Elisabet E Manasanch, Muzaffar H Qazilbash, Qaiser Bashir, Simrit Parmar, Robert Z O..., Nature
• Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191  
  Sheeba K Thomas, Robert Z Orlowski, Hans C Lee, Clinical Cancer Research

Abstracts/Posters

• A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)
  Robert Z. Orlowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)
  Robert Z. Orlowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)Clinically Relevant Abstract
  Robert Z. Orlowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Cord Blood Regulatory T Cells Prevent Mutiple Myeloma Progression By Suppressing Inflammation
  Robert Z. Orlowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible f...
  Robert Z. Orlowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Outcomes of Lenalidomide Retreatment with Novel Triplet Regimens in Multiple Myeloma Patients Progressing on Lenalidomide-Based Maintenance Therapy: A Single Center Re...
  Robert Z. Orlowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
  Robert Z. Orlowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans
  Robert Z. Orlowski, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• Addressing Current Questions and Controversies in the Management of Multiple Myeloma, Amyloidosis and Waldenstr_m Macroglobulinemia (Part 2 of a 2-Part Series) 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Updated Results of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myel... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• African-American Patients with Monoclonal Gammopathy Have a Reduced Risk of Transformation to Clinical Myeloma: Results of a Prospective Study SWOG S0120 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Outcome of Autologous Stem Cell Transplantation in Waldenström's Macroglobulinemia 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Longer Term Follow up of the  Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) w... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Older Age As a Prognostic Factor for Overall Survival for Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Join now to see all